Final Phase IIa Study Results Evaluating the CXCR4 Antagonist BL-8040 in Combination with Cytarabine (Ara-C) for the Treatment of Relapsed/Refractory AML Patients
Year: 2016
Type: article
Study design: Clinical Trial
Authors: Gautam Borthakur, Martin Tallman, Yishai Ofran, James Foran, Geoffrey Uy, John DiPersio, Arnon Nagler, Jacob Rowe, Margaret Showel, Jessica Altman, Amnon Peled, Michal Abraham, Yaron Pereg, Abi Vainstein, Galia Oberkovitz, Tzipi Lustig, Arnon Aharon, Carlos Bueso-Ramos, Jorge Cortes, Michael Andreeff
Institutions: The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Rambam Health Care Campus, Mayo Clinic, Mayo Clinic in Florida, Washington University in St. Louis, Sheba Medical Center, Shaare Zedek Medical Center, Bikur Cholim Hospital, Johns Hopkins University, Northwestern University, Biokine (Israel), BioLineRx Ltd. (Israel)
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2521400229